# Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

> **NCT06082102** · PHASE3 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 324 (estimated)

## Conditions studied

- Relapsed/Refractory Marginal Zone Lymphoma

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06082102
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-19
- **Primary completion:** 2028-08-31
- **Final completion:** 2030-02-25
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06082102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06082102, "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06082102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*